Witters L M, Curley E M, Kumar R, Chinchilli V M, Harvey J P, Crebbin V, Harvey H A, Lipton A
Department of Medicine and Center for Biostatistics and Epidemiology, The Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Clin Cancer Res. 1995 May;1(5):551-7.
In this study we determined the levels of the epidermal growth factor receptor (EGFR) in the urine of patients with squamous cell carcinoma compared to levels in the urine of normal volunteers and patients with nonsquamous cell carcinoma. A 24-h urine specimen was collected from 50 normal volunteers, 50 patients with nonsquamous cell carcinoma, and 42 patients with squamous cell carcinoma. An ELISA using mAbs to the external domain of the EGFR was used to measure levels of the receptor in the urine samples. Measurement of the EGFR ectodomain in the 24-h urine specimens showed detectable levels in 15 (36%) of 42 squamous cell carcinoma patients compared to 3 (6%) of 50 controls and 8 (16%) of 50 nonsquamous patients. It was also observed that 10 (53%) of 19 patients with metastatic squamous cell carcinoma had detectable EGFR ectodomain levels compared to 5 (22%) of 23 squamous cell patients with localized disease. Thus, we concluded that the EGFR ectodomain was detectable in the urine in a significantly higher number of patients with squamous cell carcinoma than normal volunteers or patients with nonsquamous cell carcinoma.
在本研究中，我们测定了鳞状细胞癌患者尿液中表皮生长因子受体（EGFR）的水平，并与正常志愿者和非鳞状细胞癌患者尿液中的水平进行比较。从50名正常志愿者、50名非鳞状细胞癌患者和42名鳞状细胞癌患者中收集了24小时尿液样本。使用针对EGFR胞外域的单克隆抗体的酶联免疫吸附测定（ELISA）来测量尿液样本中受体的水平。对24小时尿液样本中EGFR胞外域的测量显示，42名鳞状细胞癌患者中有15名（36%）可检测到EGFR水平，而50名对照组中有3名（6%），50名非鳞状细胞癌患者中有8名（16%）可检测到。还观察到，19名转移性鳞状细胞癌患者中有10名（53%）可检测到EGFR胞外域水平，而23名局限性鳞状细胞癌患者中有5名（22%）可检测到。因此，我们得出结论，与正常志愿者或非鳞状细胞癌患者相比，鳞状细胞癌患者尿液中可检测到EGFR胞外域的人数显著更多。
